T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties.

Clonal deletion and clonal anergy are well established mechanisms of peripheral tolerance. A role has also been described for clonal suppression by regulatory cells in the induction of peripheral tolerance to a variety of antigens. However, it has been difficult to isolate regulatory cells and to define their mechanism of action. We have recently reported the in vitro generation and characterization of a novel subset of CD4(+) T cells that have regulatory properties and are able to suppress antigen-specific immune responses in vitro and in vivo. These T-regulatory 1 (Tr1) cells are defined by their unique profile of cytokine production and make high levels of IL-10 and TGF-beta, but no IL-4 or IL-2. The IL-10 and TGF-beta produced by these cells mediate the inhibition of primary naive T cells in vitro. There is also evidence that Tr1 cells exist in vivo, and we have documented the presence of high IL-10-producing CD4(+) T cells in patients with severe combined immunodeficiency who have received allogeneic stem-cell transplants. These findings support the notion that Tr1 cells are involved in the regulation of peripheral tolerance and that they could potentially be used as a cellular therapy to modulate immune responses in vivo.

[1]  M. Roncarolo,et al.  A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. , 1999, Journal of immunology.

[2]  N. Van Rooijen,et al.  Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. , 1997, Journal of immunology.

[3]  R. Locksley,et al.  Altered Immune Responses in Interleukin 10 Transgenic Mice , 1997, The Journal of experimental medicine.

[4]  B. Benacerraf,et al.  Suppressor cells and immunoregulation. , 1984, Annual review of immunology.

[5]  F. Ruscetti,et al.  Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. , 1999, Journal of immunology.

[6]  L. Li,et al.  Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines. , 1999, Journal of immunology.

[7]  J. Rolland,et al.  Immunotherapy of allergy: anergy, deletion, and immune deviation. , 1998, Current opinion in immunology.

[8]  T. Mosmann,et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.

[9]  P. Subramaniam,et al.  Mechanism of Interleukin-10 Inhibition of T-Helper Cell Activation by Superantigen at the Level of the Cell Cycle , 1999 .

[10]  M. Sporn,et al.  Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. O’Garra,et al.  Cytokines induce the development of functionally heterogeneous T helper cell subsets. , 1998, Immunity.

[12]  J. D. de Vries,et al.  Chimerism and tolerance to host and donor in severe combined immunodeficiencies transplanted with fetal liver stem cells. , 1993, The Journal of clinical investigation.

[13]  H. Boehmer,et al.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes , 1988, Nature.

[14]  F. Powrie,et al.  Interleukin 10 is a growth factor for a population of regulatory T cells , 1998, Gut.

[15]  G. Trinchieri,et al.  Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. , 1998, Journal of immunology.

[16]  J. Abrams,et al.  Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4. , 1990, Journal of immunology.

[17]  J. D. de Vries,et al.  A SCID patient reconstituted with HLA-incompatible fetal stem cells as a model for studying transplantation tolerance. , 1991, Blood cells.

[18]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[19]  R. de Waal Malefyt,et al.  High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells , 1994, The Journal of experimental medicine.

[20]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[21]  R. Lechler,et al.  Anergic T cells as suppressor cells in vitro. , 1994, Science.

[22]  H. Weiner,et al.  Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. , 1994, Science.

[23]  CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens. , 1997, Journal of immunology.

[24]  W. van Eden,et al.  Dose-dependent induction of distinct anergic phenotypes: multiple levels of T cell anergy. , 1999, Journal of immunology.

[25]  M. Goldman,et al.  Interleukin‐10 differentially regulates B7‐1 (CD80) and B7‐2 (CD86) expression on human peripheral blood dendritic cells , 1995, European journal of immunology.

[26]  D. Mason,et al.  Control of immune pathology by regulatory T cells. , 1998, Current opinion in immunology.

[27]  R. Coffman,et al.  Transgenic Interleukin 10 Prevents Induction of Experimental Autoimmune Encephalomyelitis , 1999, The Journal of experimental medicine.

[28]  F. Autschbach,et al.  T cells of the human intestinal lamina propria are high producers of interleukin-10 , 1997, Gut.

[29]  W. van Eden,et al.  Anergic T cells actively suppress T cell responses via the antigen‐presenting cell , 1998, European journal of immunology.

[30]  R. Schwartz,et al.  Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo , 1987, The Journal of experimental medicine.

[31]  H. Jun,et al.  A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. , 1996, Journal of autoimmunity.

[32]  J. Buer,et al.  Interleukin 10 Secretion and Impaired Effector Function of Major Histocompatibility Complex Class II–restricted T Cells Anergized In Vivo , 1998, The Journal of experimental medicine.

[33]  R. Schwartz,et al.  Models of T Cell Anergy: Is There a Common Molecular Mechanism? , 1996 .

[34]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[35]  C. Figdor,et al.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression , 1991, The Journal of experimental medicine.

[36]  J. D. de Vries,et al.  Autoreactive T cell clones specific for class I and class II HLA antigens isolated from a human chimera , 1988, The Journal of experimental medicine.

[37]  M. Roncarolo,et al.  High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths , 1999, Bone Marrow Transplantation.

[38]  R. Coffman,et al.  A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells , 1996, The Journal of experimental medicine.

[39]  I. Bernard,et al.  Transforming Growth Factor β (TGF-β)-dependent Inhibition of T Helper Cell 2 (Th2)-induced Autoimmunity by Self–Major Histocompatibility Complex (MHC) Class II–specific, Regulatory CD4+ T Cell Lines , 1997, The Journal of experimental medicine.

[40]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[41]  J. D. de Vries,et al.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells , 1996, The Journal of experimental medicine.

[42]  B. Rocha,et al.  Peripheral selection of the T cell repertoire. , 1991, Science.

[43]  R. Schwartz,et al.  Anergy and Cytokine-Mediated Suppression as Distinct Superantigen-Induced Tolerance Mechanisms in Vivo , 1999, The Journal of experimental medicine.

[44]  S. Nakagawa,et al.  Interferon‐γ and interleukin‐10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7‐1) expression , 1996, European journal of immunology.